FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367304930> ?p ?o ?g. }

• W4367304930 abstract "<h3>Objective:</h3> We explored whether striatal dopaminergic availability may predict Levodopa Equivalent Daily Dose (<i>LEDD</i>) requirements in People with early Parkinson’s disease (<i>PD, PwP</i>). <h3>Background:</h3> Personalised medicine driven by clinical biomarkers is the state-of-art management approach for PD. Whether pattern of striatal dopaminergic deficiency (demonstrated by single-photon emission CT (SPECT) scanning with ¹²³I-Ioflupane, <i>DaTSCAN</i>) could serve as a biomarker predicting levodopa requirement in early PD is not known. <h3>Design/Methods:</h3> Participants with early PD (disease duration (DD) ≤5 years, Hoehn and Yahr (HY) ≤3) who underwent DaTSCAN as a part of a clinical-diagnostic work up were enrolled in the “Non-motor Longitudinal International Study” (UK National Institute for Health Research Clinical Research Network Number 10084) and were included in this cross-sectional analysis. Specific DaTSCAN binding ratios were analyzed for each striatum, caudate and putamen and the z-scores were derived normalizing the images to age and gender-matched healthy controls from the European-Database-of-DaTSCAN-of-healthy-controls (ENC-DAT). The normality of data distribution was tested (One-sample Kolmogorov–Smirnov test) and descriptive statistics provided. Using linear regression analysis, we explored the impact of DaT-uptake z-scores for more severely affected putamen, caudate and striatum on the LEDD. Statistically significant predictors identified in the univariable analysis were included in the multivariable analysis with DD and HY as additional independent variables. (SPSS, Version 28). <h3>Results:</h3> 43 PwP (30.2 %female; age: 61.91±11.45years; DD: 2(0–5)years; HY: 2(1–3); LEDD: 424.27±342.62 mg) were assessed 19.12±13.11 months following the DaTSCAN. In a multivariable linear regression analysis, when adjusted for DD and HY, z-caudate (B=−134.073, 95% CI −262.715 – −5.431, <i>p</i>=0.042) and z-striatum (B=−162.137, 95% CI −306.306 – −17.967, <i>p</i>=0.028), were statistically significant predictors of LEDD, while z-putamen was not (<i>p</i>=0.086). <h3>Conclusions:</h3> DaT-uptake z-scores for caudate and striatum may serve as biomarkers that could predict LEDD requirement and guide treatment decisions towards personalized care for PwP. <b>Disclosure:</b> The institution of Ms. Rukavina has received research support from NIHR BRC. The institution of Ms. Rukavina has received research support from Parkinson’s UK. Ms. Rukavina has received personal compensation in the range of $0-$499 for serving as a Speaker or Writer with Valid Insight, Profile Pharma and Britannia. . Nicola Mulholland has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AAA. Nicola Mulholland has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sirtex. Ben Corcoran has nothing to disclose. Ms. Staunton has nothing to disclose. Magdalena Krbot Skoric has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Rota has nothing to disclose. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AbbVie. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GKC. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bial. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cynapsus. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lobsor. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Stada. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zambon. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Profile Pharma. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Synovion. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theravance. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Scion. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Britannia. Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Britannia. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Britannia. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Zambon. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Boehringer Ingelheim. An immediate family member of Mrs. Rizos has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Nature Parkinson’s Journal. The institution of an immediate family member of Mrs. Rizos has received research support from EU. The institution of an immediate family member of Mrs. Rizos has received research support from Parkinson’s UK. The institution of an immediate family member of Mrs. Rizos has received research support from Parkinson’s Foundation. The institution of an immediate family member of Mrs. Rizos has received research support from Wellcome trust. The institution of an immediate family member of Mrs. Rizos has received research support from MRC. An immediate family member of Mrs. Rizos has received intellectual property interests from a discovery or technology relating to health care. An immediate family member of Mrs. Rizos has received publishing royalties from a publication relating to health care. An immediate family member of Mrs. Rizos has received publishing royalties from a publication relating to health care. Prof. Ray Chaudhuri has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Advisory board recent: AbbVie, UCB, GKC, Bial, Cynapsus, Lobsor, Stada, Zambon, Profile Pharma, Synovion, Roche, Therevance, Scion, Britannia, Acadia, 4D Pharma. Prof. Ray Chaudhuri has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AbbVie, Britannia, UCB, Zambon, Novartis, Boeringer Ingelheim, Bial, Kyowa Kirin, SK Pharma . Prof. Ray Chaudhuri has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for GMC. The institution of Prof. Ray Chaudhuri has received research support from EU Horizon 2020, Parkinson’s UK, NIHR, Parkinson’s Foundation, Wellcome Trust Aacdemic grants over 2 years ago: Kirby Laing Foundation, MRC. Prof. Ray Chaudhuri has received publishing royalties from a publication relating to health care." @default.
• W4367304930 created "2023-04-29" @default.
• W4367304930 creator A5000880712 @default.
• W4367304930 creator A5007310747 @default.
• W4367304930 creator A5032064052 @default.
• W4367304930 creator A5032235791 @default.
• W4367304930 creator A5050179468 @default.
• W4367304930 creator A5061304926 @default.
• W4367304930 creator A5075066106 @default.
• W4367304930 creator A5078254228 @default.
• W4367304930 date "2023-04-25" @default.
• W4367304930 modified "2023-09-28" @default.
• W4367304930 title "DaT-uptake z-scores for Caudate and Striatum Predict Levodopa Requirement in Early Parkinson’s Disease (S37.009)" @default.
• W4367304930 doi "https://doi.org/10.1212/wnl.0000000000203240" @default.
• W4367304930 hasPublicationYear "2023" @default.
• W4367304930 type Work @default.
• W4367304930 citedByCount "0" @default.
• W4367304930 crossrefType "proceedings-article" @default.
• W4367304930 hasAuthorship W4367304930A5000880712 @default.
• W4367304930 hasAuthorship W4367304930A5007310747 @default.
• W4367304930 hasAuthorship W4367304930A5032064052 @default.
• W4367304930 hasAuthorship W4367304930A5032235791 @default.
• W4367304930 hasAuthorship W4367304930A5050179468 @default.
• W4367304930 hasAuthorship W4367304930A5061304926 @default.
• W4367304930 hasAuthorship W4367304930A5075066106 @default.
• W4367304930 hasAuthorship W4367304930A5078254228 @default.
• W4367304930 hasConcept C126322002 @default.
• W4367304930 hasConcept C2779134260 @default.
• W4367304930 hasConcept C2779734285 @default.
• W4367304930 hasConcept C2780062018 @default.
• W4367304930 hasConcept C2780304432 @default.
• W4367304930 hasConcept C2781423529 @default.
• W4367304930 hasConcept C513476851 @default.
• W4367304930 hasConcept C71924100 @default.
• W4367304930 hasConceptScore W4367304930C126322002 @default.
• W4367304930 hasConceptScore W4367304930C2779134260 @default.
• W4367304930 hasConceptScore W4367304930C2779734285 @default.
• W4367304930 hasConceptScore W4367304930C2780062018 @default.
• W4367304930 hasConceptScore W4367304930C2780304432 @default.
• W4367304930 hasConceptScore W4367304930C2781423529 @default.
• W4367304930 hasConceptScore W4367304930C513476851 @default.
• W4367304930 hasConceptScore W4367304930C71924100 @default.
• W4367304930 hasLocation W43673049301 @default.
• W4367304930 hasOpenAccess W4367304930 @default.
• W4367304930 hasPrimaryLocation W43673049301 @default.
• W4367304930 hasRelatedWork W1488920069 @default.
• W4367304930 hasRelatedWork W1973642029 @default.
• W4367304930 hasRelatedWork W1991706223 @default.
• W4367304930 hasRelatedWork W2034349148 @default.
• W4367304930 hasRelatedWork W2072369641 @default.
• W4367304930 hasRelatedWork W2148810891 @default.
• W4367304930 hasRelatedWork W2156186003 @default.
• W4367304930 hasRelatedWork W2378738157 @default.
• W4367304930 hasRelatedWork W2402620789 @default.
• W4367304930 hasRelatedWork W2463734130 @default.
• W4367304930 isParatext "false" @default.
• W4367304930 isRetracted "false" @default.
• W4367304930 workType "article" @default.